Table 3 Treatment of Hepatocellular Carcinoma in India
From: HCC surveillance results in earlier HCC detection: results from an Indian cohort
BCLC stage | No treatment n (%) | Chemo-embolization n (%) | Resection n (%) | Sorafenib n (%) | Liver transplant n (%) | ETOH injection n (%) | RFA n (%) | TACE n (%) |
|---|---|---|---|---|---|---|---|---|
0 | 1 (5.00%) | 0 | 0 | 0 | 0 | 0 | 1 (50.0%) | 0 |
A | 6 (46.0%) | 3 (21.4%) | 1 (7.7%) | 0 | 1 (7.7%) | 0 | 2 (14.3%) | 0 |
B | 36 (69.2%) | 5 (9.6%) | 5 (9.6%) | 2 (3.9%) | 0 | 0 | 2 (3.9%) | 2 (3.9%) |
C | 29 (87.9%) | 1 (3.0%) | 0 | 2 (6.1%) | 0 | 1 (3.0%) | 0 | 0 |
D | 53 (88.3%) | 1 (1.7%) | 0 | 0 | 3 (5.0%) | 0 | 0 | 2 (3.3%) |